Gerry Brunk

Bio

Gerry focuses on investments in the therapeutics and medical device sectors. With 19 years of investment, consulting and entrepreneurial experience, he has helped build life science companies at all stages of development. Before joining Lumira Capital in 2002 to establish our Cambridge office, Gerry was an entrepreneur in the life science sector, founding and serving in a variety of management and board capacities at several venture capital-funded companies. Earlier in his career he was an engagement manager in the health care practice of The Boston Consulting Group, where he advised pharmaceutical and biotechnology firms on strategic issues involving portfolio management, product licensing, R&D productivity, new product introductions, acquisitions, and post-merger integration. Gerry began his career as a member of the investment banking group of Credit Suisse First Boston in New York where his clients included public and private health care companies. Gerry’s current or past board roles and investment responsibilities include Archemix, Cardiac Dimensions, MAKO Surgical (NASDAQ: MAKO), NephroGenex, Pharmasset (NASDAQ: VRUS), PharmAthene (AMEX: PIP), and Targanta Therapeutics (now NASDAQ: MDCO). He holds an MBA from Stanford University Graduate School of Business and graduated Phi Beta Kappa with a BA from the University of Virginia, where he studied biology and economics.